• Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestones • Company expects to complete early market access regulatory approval submissions for Herlystic™ (“OST-HER2" or “daznelimgene lisbac”) in the U.S., U.K., Europe and Australia in the fourth quarter of 2026
October 19, 2026
· 8 min read
